Stock listing

LSE:AVCT Avacta Group PLC Share Price

Home listing (LSE) of Avacta Group PLC

Follow Avacta Group PLC into a list and get an email when it puts out news.

Share price · LSE:AVCT

59.00p GBX (pence) +2.20 (+3.9%)

Close on Nov 20, 2026

Past year -24.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
59.00p – 63.00p GBX (pence)Nov 20, 2026
Volume
2.05M sharesNov 20, 2026
Market cap
£258.2M GBPAt the close on Nov 20, 2026 · price × 437.6M shares outstanding
52-week range
48.00p – 92.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£1.22M GBPMedian day 1.38M shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Avacta Group PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:AVCT · Home59.00p GBX (pence)+2.20 (+3.9%)2,050,02060.16p63.00p59.00p56.80pClose on Nov 20, 2026
OTC:AVCTF$0.77 USD0.00 (0.0%)—$0.77$0.77$0.77$0.77Close on Nov 6, 2026
Frankfurt:RTQ1€0.705 EUR+0.035 (+5.2%)—€0.705€0.705€0.705€0.670Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:AVCT · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
59.00p+2.20+3.9%60.16p63.00p59.00p2,050,020
56.80p-0.20-0.4%56.58p59.00p56.00p1,434,281
57.00p-0.10-0.2%56.95p58.00p56.00p1,169,757
57.10p-1.90-3.2%58.43p60.00p56.00p797,066
59.00p-2.60-4.2%59.25p60.00p56.00p1,350,702
61.60p+1.90+3.2%60.00p63.00p58.00p2,041,442
59.70p+5.70+10.6%54.44p60.00p53.50p5,136,557
54.00p+0.60+1.1%52.89p54.50p52.00p3,107,309
53.40p-0.40-0.7%54.00p55.00p52.60p2,157,191
53.80p-1.80-3.2%55.20p56.00p53.00p5,762,517
55.60p-1.90-3.3%56.90p58.00p55.20p3,985,363
57.50p0.000.0%58.00p58.50p55.00p5,808,991
57.50p-1.20-2.0%58.65p60.00p56.68p2,615,665
58.70p-1.80-3.0%60.25p61.00p58.00p2,168,626
60.50p-0.50-0.8%61.00p61.00p60.00p833,122
61.00p-0.50-0.8%61.68p62.00p60.45p712,501
61.50p0.000.0%61.74p62.00p61.00p805,573
61.50p-1.00-1.6%62.80p63.00p60.00p2,234,097
62.50p-0.80-1.3%65.39p66.00p62.00p1,076,398
63.30p-0.80-1.2%65.35p67.00p63.00p1,371,247
64.10p-1.60-2.4%65.50p66.00p63.90p913,349
65.70p-2.60-3.8%67.50p69.00p65.00p1,443,970
68.30p+0.30+0.4%68.00p70.00p67.00p1,979,351
68.00p+1.00+1.5%66.50p69.00p66.00p1,623,292
67.00p+2.00+3.1%64.00p67.00p64.00p3,643,200
65.00p+0.80+1.2%63.50p65.00p62.55p1,435,313
64.20p+0.70+1.1%63.50p64.20p62.00p1,257,890
63.50p-0.50-0.8%63.50p65.00p62.33p1,195,897
64.00p-1.50-2.3%65.50p66.00p63.25p1,379,668
65.50p+1.50+2.3%65.00p68.00p63.00p2,555,031
64.00p+0.50+0.8%63.50p67.76p62.00p4,588,047
63.50p-4.50-6.6%68.50p69.00p63.22p2,974,506
68.00p-4.00-5.6%68.50p70.00p66.00p4,698,688
72.00p0.000.0%72.00p72.00p72.00p0
72.00p0.000.0%72.00p72.00p72.00p0
72.00p0.000.0%72.00p72.00p72.00p0
72.00p0.000.0%72.00p72.00p72.00p612,341
72.00p-0.50-0.7%72.50p74.00p71.00p614,155
72.50p-0.30-0.4%74.00p75.00p72.00p532,003
72.80p-1.20-1.6%75.50p77.00p70.73p1,880,265
74.00p-1.00-1.3%74.50p75.00p73.00p358,933
75.00p0.000.0%75.00p76.00p72.94p748,154
75.00p-3.00-3.8%78.00p79.00p74.00p1,081,422
78.00p0.000.0%78.00p81.00p76.00p1,156,082
78.00p+2.00+2.6%75.50p80.00p75.00p1,335,884
76.00p-2.60-3.3%79.00p81.00p74.00p3,085,032
78.60p-1.40-1.8%84.50p88.00p78.00p7,733,552
80.00p+4.50+6.0%76.00p80.80p74.00p4,504,015
75.50p+2.50+3.4%73.00p77.68p72.00p3,767,784
73.00p+4.10+6.0%70.50p73.00p69.00p1,612,301
68.90p-2.10-3.0%71.50p74.00p68.90p1,083,209
71.00p+2.50+3.6%68.50p72.00p68.00p2,210,092
68.50p+2.00+3.0%66.50p70.00p66.00p1,267,836
66.50p-1.00-1.5%67.50p69.00p65.00p411,606
67.50p+1.50+2.3%67.00p69.00p65.00p477,724
66.00p-1.00-1.5%67.50p69.00p66.00p426,442
67.00p-1.00-1.5%68.00p69.00p64.00p1,676,665
68.00p-0.20-0.3%68.00p71.00p67.00p1,453,413
68.20p-0.80-1.2%68.50p69.00p67.00p672,520
69.00p-0.20-0.3%68.50p69.00p67.00p441,740
69.20p-0.30-0.4%70.50p72.00p67.00p939,396
69.50p+0.70+1.0%69.50p74.00p68.00p1,471,000
68.80p+0.80+1.2%68.00p71.00p67.00p736,008
68.00p-0.50-0.7%68.50p70.00p66.00p799,037
68.50p+2.50+3.8%66.00p70.00p65.93p1,700,898

Splits

2 splits since 2006 · LSE:AVCT · every price before a split is adjusted for it

DayRatioWhat
1-for-100Consolidation
5-for-1Split
Ticker
LSE:AVCT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
GBX

What changed lately

Latest news

All Avacta Group PLC news

Avacta Group PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
70 in the last 12 months · 491 in all · newest Nov 19, 2026 · oldest 2003
Calls
21 calls with a replay · 21 with a transcript · latest Oct 15, 2026
Decks
27 decks · latest March 2026

Where Avacta Group PLC is listed

ListingExchangeCountryCurrency
LSE:AVCT · Home listing · This pageLSEUnited KingdomGBX
OTC:AVCTFOTCUnited StatesUSD
LS Exchange:A2ADP0LS ExchangeGermanyEUR
Lang & Schwarz:A2ADP0Lang & SchwarzGermanyEUR
gettex:RTQ1gettexGermanyEUR
Dusseldorf:RTQ1DusseldorfGermanyEUR
Frankfurt:RTQ1FrankfurtGermanyEUR
Stuttgart:RTQ1StuttgartGermanyEUR

Valuation

EV/sales 2,281× against a median of 45.3×: 7th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
£257.8M GBP
P/E
Loss
EV/sales
2,281×
EV/EBITDA
Negative EBITDA
Price/book
68.5×
Gross margin
100.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
5.3×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Avacta Group PLC · LSE:AVCTUS$337.8MUS$337.2Mn/a2,281×n/a68.5×n/a5.3×n/a
Alector, Inc. · NASDAQ:ALECUS$347.6MUS$208.9M8.4×1.2×4.9×3.0×23.9%0.0×1.72
Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617US$347.3MUS$296.6Mn/a232×n/a4.9×−389.6%0.0×n/a
AbClon, Inc. · KRX:174900US$346.1MUS$319.1Mn/a80.9×n/a8.8×−328.3%0.0×n/a
Onconic Therapeutics, Inc. · KRX:476060US$344.4MUS$297.9M19.1×4.9×n/a5.4×29.5%0.0×n/a
Lyell Immunopharma, Inc. · NASDAQ:LYELUS$339.3MUS$196.5Mn/a13,099×n/a1.8×n/a0.2×1.51
Inovio Pharmaceuticals, Inc. · NASDAQ:INOUS$329.7MUS$7.56Bn/a25,303×3.4×n/an/an/a0.70
Larimar Therapeutics, Inc. · NASDAQ:LRMRUS$328.6MUS$204.7Mn/an/an/a3.2×n/a0.1×1.48
CytoDyn Inc. · OTC:CYDYUS$326.4MUS$345.8Mn/an/an/an/an/an/a0.44
C4 Therapeutics, Inc. · NASDAQ:CCCCUS$325.7MUS$175.5Mn/a5.4×n/a1.4×−282.2%0.2×1.46
Laekna, Inc. · HKEX:2105US$322.8MUS$154.7Mn/a9.7×n/a1.8×−214.9%0.0×n/a
Median of the othersUS$334.5MUS$252.8M13.8×45.3×4.1×3.1×−248.6%0.0×1.47

Forecasts

Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
90.50 GBX · Analysts' mean
EPS, year to Dec 2026
-0.072 · 3 analysts

Team and board

Officers

OfficerRole
Brian HahnCompany Secretary
David LiebowitzChief Medical Officer
Francis WilsonChief Scientific Officer

Board

DirectorRole
Mats BlomDirector
Patrick VinkDirector
Richard HughesNon-executive Director

Events

Calls

CallWhenStatus
Avacta Group (LSE:AVCT) Q2 2026 Earnings CallThu, Oct 15, 2026 · 11:00 AM ETReplay
Avacta Group (LSE:AVCT) — Interim ResultsThu, Oct 15, 2026 · 11:00 AM ETReplay
Avacta Group (LSE:AVCT) Q4 2025 Earnings CallTue, May 19, 2026 · 9:00 AM ETReplay
Avacta Group (LSE:AVCT) — Phase 1b Faridoxorubicin (AVA6000) Salivary Gland Cancer Data ReleaseWed, Dec 17, 2025 · 5:00 AM ETReplay
Avacta Group (LSE:AVCT) Q2 2025 Earnings CallTue, Sep 30, 2025 · 9:00 AM ETReplay
Avacta Group (LSE:AVCT) Q4 2024 Earnings CallFri, Jun 06, 2025 · 9:00 AM ETReplay
Avacta Group (LSE:AVCT) — Preliminary ResultsFri, Jun 06, 2025 · 6:00 AM ETReplay
Avacta Group (LSE:AVCT) Q2 2024 Earnings CallMon, Sep 30, 2024 · 9:00 AM ETReplay
Avacta Group (LSE:AVCT) — Investor PresentationMon, Sep 30, 2024 · 6:00 AM ETReplay
Avacta Group (LSE:AVCT) Q4 2023 Earnings CallTue, Apr 30, 2024 · 9:00 AM ETReplay
All 21 calls
CallWhenStatus
Avacta Group (LSE:AVCT) — Review of the AVA6000 clinical trial’s Phase 1a dataWed, Dec 13, 2023 · 6:00 AM ETReplay
Avacta Group (LSE:AVCT) Q2 2023 Earnings CallThu, Sep 28, 2023 · 9:00 AM ETReplay
Avacta Group (LSE:AVCT) — Interim ResultsThu, Sep 28, 2023 · 6:00 AM ETReplay
Avacta Group (LSE:AVCT) — Post AGM Presentation and Investor Q&AWed, Jun 28, 2023 · 6:00 AM ETReplay
Avacta Group (LSE:AVCT) Q4 2022 Earnings CallTue, Apr 25, 2023 · 9:00 AM ETReplay
Avacta Group (LSE:AVCT) Q4 2021 Earnings CallWed, Apr 06, 2022 · 9:00 AM ETReplay
Avacta Group (LSE:AVCT) — Final ResultsWed, Apr 06, 2022 · 6:00 AM ETReplay
Avacta Group (LSE:AVCT) Q2 2021 Earnings CallThu, Sep 30, 2021 · 9:00 AM ETReplay
Avacta Group (LSE:AVCT) — Interim ResultsThu, Sep 30, 2021 · 5:30 AM ETReplay
Avacta Group (LSE:AVCT) — Business Update and Q&AMon, Jun 21, 2021 · 5:00 AM ETReplay
Avacta Group (LSE:AVCT) — Interim results for the 6 months ended 30 June 2020Mon, Sep 28, 2020 · 5:30 AM ETReplay

Results days

QuarterResultsShare move
Q2 2025Sep 30, 2025+20.6%
Quarter to Mar 31, 2025Jun 6, 2025 · Before open−5.1%
Q2 2024Sep 30, 2024−12.6%
Q1 2023Apr 25, 2023 · Before open−2.5%
Q2 2022Sep 30, 2022 · Before open−3.5%
Q1 2022Apr 6, 2022+39.1%
Q2 2021Sep 30, 2021+2.9%
Q1 2021Apr 22, 2021−9.0%
Q4 2020Mar 29, 2021−8.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck25 slidesMarch 2026
TD Cowen 46th Annual Healthcare Conference 2026Conference14 slidesMarch 2026
Q2 2025 Earnings PresentationEarnings9 slidesSep 30, 2025
Shareholder Meeting (July 2025)Shareholder meeting18 slidesJul 2, 2025
Investor Presentation (March 2025)Investor deck28 slidesMarch 2025
Avacta Therapeutics — Investor Presentation (January 2025)Investor deck34 slidesJanuary 2025
H1 2024 Earnings PresentationEarnings28 slidesSep 30, 2024
FY2023 Earnings PresentationEarnings27 slidesApr 30, 2024
H1 2023 Earnings PresentationEarnings33 slidesSep 28, 2023
Shareholder Meeting (June 2023)Shareholder meeting46 slidesJun 28, 2023
All 27 decks
DeckKindSlidesDate
FY2022 Earnings PresentationEarnings33 slidesApr 25, 2023
Investor Day (February 2023)Investor day120 slidesFeb 23, 2023
FY2021 Earnings PresentationEarnings28 slidesApr 6, 2022
Investor Presentation (February 2022)Investor deck23 slidesFebruary 2022
Immunotherapy World Congress 2021Conference21 slidesNovember 2021
H1 2021 Earnings PresentationEarnings25 slidesSep 30, 2021
Investor Presentation (June 2020)Investor deck21 slidesJun 5, 2020
Investor Presentation (February 2020)Investor deck13 slidesFebruary 2020
H1 2019 Earnings PresentationEarnings22 slidesApr 9, 2019
Investor Day (February 2019)Investor day67 slidesFeb 14, 2019
Investor Day (February 2018)Investor day41 slidesFeb 7, 2018
H1 2016 Earnings PresentationEarnings32 slidesApr 25, 2016
FY2013 Earnings PresentationEarnings19 slidesNov 16, 2013
H1 2013 Earnings PresentationEarnings19 slidesApr 30, 2013
FY2012 Earnings PresentationEarnings16 slidesOct 23, 2012
H1 FY2012 Earnings PresentationEarnings24 slidesApr 25, 2012
FY2011 Earnings PresentationEarnings20 slidesOct 25, 2011

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new Ordinary Shares
Update: £12.5M · GBX 68 a share · Zeus Capital Limited +2
Dealers: Zeus Capital Limited (lead), Beech Hill Securities, Inc., Strand Hanson
Buyers: Richard Hughes (£500,000, 735,294 Subscription Shares); Patrick Vink (£75,000, 110,294 Subscription Shares); David Bryant (£50,000, 73,529 Subscription Shares); Mats Blom (£35,000, 51,470 Subscription Shares); Zeus Capital Limited (180,001 Ordinary Shares for £122,400.68)
Insiders: Directors Richard Hughes, Patrick Vink, David Byrant and Mats Blom subscribed for 970,587 new Ordinary Shares, approximately £660,000
Use of proceeds: Extend cash runway into Q2 2027 and fund the company through multiple pipeline value inflection points
Oct 6, 2026US$16.59M
Private placement of placing Shares
Closed: £16M raised · GBX 63 a share · Zeus Capital Limited
Dealers: Zeus Capital Limited (lead)
Use of proceeds: Working capital to progress R&D programs into 2H 2026, including the faridoxorubicin Phase 1b trial and planned FAP-EXd Phase Ia trial
Nov 3, 2025US$21.46M
Private placement of new ordinary shares
Announced: £3.25M · GBX 50 a share · Zeus Capital Limited
Dealers: Zeus Capital Limited (lead)
Use of proceeds: To settle the October 2025 quarterly repayment of the unsecured convertible bond
Aug 29, 2025US$4.38M
Private placement of new ordinary shares
Announced: £3.25M · GBX 30 a share · Zeus Capital Limited +1
Dealers: Zeus Capital Limited (lead), Turner Pope Investments (TPI) Limited
Use of proceeds: To settle the July quarterly repayment of the unsecured convertible bond due on 21 July 2025
Jul 17, 2025US$4.36M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue113.0K113.0K2.85M9.65M2.94M2.14M3.89M2.76M2.73M
Cost of revenue1.28M1.50M15.0K2.41M5.44M3.12M3.80M2.93M2.52M
Gross profit113.0K113.0K2.84M7.24M-2.50M-973.0K86.1K-164.0K211.0K
Research and development16.9M14.3M13.1M11.1M13.5M8.89M5.55M2.73M2.03M
Selling, general and administrative9.24M12.0M2.91M2.29M4.94M1.05M8.46M8.52M7.18M
Operating income-30.3M-32.6M-22.0M-25.5M-29.1M-16.9M-12.7M-9.45M-7.97M
Depreciation and amortization1.28M1.44M1.28M3.01M2.38M2.15M2.79M2.03M1.58M
EBITDA-29.0M-31.1M-20.7M-22.5M-26.7M-14.7M-9.93M-7.41M-6.39M
Interest expense7.05M10.1M15.3M2.70M128.0K89.0K69.2K00
Income before tax-37.9M-29.0M-31.1M-41.6M-29.2M-18.9M-12.7M-10.4M-7.89M
Income tax-1.64M444.0K1.98M-4.66M-2.82M-2.46M-1.72M-1.56M-1.53M
Net income-38.4M-52.8M-24.9M-36.9M-26.3M-18.9M-11.0M-8.83M-6.37M
Earnings per share, basic-0.10-0.16-0.09-0.14-0.11-0.08-0.09-0.13-0.09

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2017
Cash and equivalents16.9M12.9M16.6M41.8M26.2M27.9M8.79M8.79M5.22M9.17M
Short-term investments20.0M4.00M
Receivables6.34M3.38M4.49M3.72M4.61M1.76M3.69M3.69M370.0K2.48M
Inventory02.58M1.68M189.0K248.0K156.0K156.0K187.0K158.0K
Current assets23.2M40.2M28.0M55.6M34.7M53.3M13.5M13.5M8.20M15.8M
Property, plant and equipment4.34M4.79M3.08M3.05M3.45M
Goodwill1.54M1.54M17.0M14.2M1.54M2.31M3.83M3.83M3.83M4.66M
Total assets29.4M48.3M73.2M92.6M47.0M67.5M28.4M28.4M23.5M31.6M
Accounts payable8.95M2.80M3.73M2.49M561.0K856.0K698.0K698.0K831.0K645.0K
Current liabilities26.2M37.3M45.1M67.6M4.37M3.78M1.96M1.96M2.04M1.66M
Long-term debt0219.0K0
Total debt14.9M22.9M23.5M62.9M1.70M2.04M823.0K823.0K
Total liabilities26.9M39.0M51.4M74.2M5.78M5.53M2.60M2.60M2.04M1.66M
Shareholders' equity2.48M9.28M21.8M18.4M41.2M61.9M25.8M25.8M21.4M29.9M
Shares outstanding399.9M326.9M272.7M255.4M249.6M225.7M120.4M65.5M68.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-24.8M-23.6M-14.9M-16.4M-20.5M-10.6M-13.0M-5.47M-4.24M
Capital spending-53.0K-339.0K-1.26M-594.0K-1.31M-1.67M-2.53M-2.52M-2.13M
Free cash flow-24.8M-23.9M-16.1M-17.0M-21.8M-12.3M-15.5M-7.99M-6.37M
Cash from investing9.90M-1.43M-9.00M-25.0M18.7M-21.9M-2.53M1.48M3.87M
Cash from financing13.6M26.1M-1.30M56.9M232.0K51.6M19.1M45.0K14.0K
Share buybacks45.0K14.0K
Change in cash3.98M1.15M-25.2M15.6M-1.70M39.1M1.29M-3.95M-355.0K

Open Financials

Cap table

Built by 6ix from Avacta Group PLC’s releases · as of Nov 3, 2025

Common shares
437,633,189
Fully diluted
437,633,189

Fully diluted

LineShares
Common shares437,633,189

Share count over time

CountShares
Nov 22, 2026437,633,189

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Brian HahnCompany Secretary · Since at least Oct 27, 2025
Craig SlaterChief Operating Officer · Since Dec 23, 2013 · Appointed, no departure found
David LiebowitzChief Medical Officer · Since at least Jul 1, 2025
Francis WilsonChief Scientific Officer · Since at least Feb 9, 2026
Mats BlomDirector · Since at least Sep 14, 2026
Patrick VinkDirector · Since Jul 8, 2026
Philippe CotrelChief Commercial Officer · Since Jan 25, 2016 · Appointed, no departure found
Richard HughesNon-executive Director · Since at least May 29, 2026

Open People

Log in to ask 6ix AI your own questions about Avacta Group PLC.